Renal cell carcinoma with sarcomatoid dedifferentiation is an entity of RCC that has undergone an anaplastic transformation with both a carcinomatous and a sarcomatous component. The standard treatment in metastatic patients is immunotherapy. The aim of this article is to describe our case of metastatic recurrent RCC with sarcomatoid dedifferentiation in a 59 year old male patient treated with nephrectomy and multiple metastasectomies followed by Cabozantinib. Consecutive PET-CT scans showed no evidence of recurrence, three years after the last metastasectomy, and the patient is having currently a normal life. Sarcomatoid dedifferentiation remains a poor prognosis factor in RCC. Surgery for metastases followed by Cabozantinib may be a therapeutic option in metastatic young patients. However, a prospective randomized trial would be the best option to validate this approach.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244017 | PMC |
| http://dx.doi.org/10.18632/oncotarget.27543 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends and Outcomes in Sarcomatoid Renal Cell Carcinoma: Analysis of the National Cancer Data Base.
Eur Urol Open Sci
January 2025
Department of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Background And Objective: Our aim was to determine the clinical characteristics, temporal trends, and survival outcomes for sarcomatoid-dedifferentiated renal cell carcinoma (sRCC), as sRCC has historically had poor prognosis and a contemporary cohort has not been well characterized in a population-based study.
Methods: Data for 302 630 RCC cases from 2010 to 2019 were extracted from the National Cancer Data Base, of which 4.1% (12 329) were sRCC.
Low-Level Amplification by FISH: An Institutional Experience With a Diagnostic Dilemma.
Int J Surg Pathol
November 2024
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
() amplification via fluorescence in-situ hybridization (FISH) is the gold standard test used for confirming the diagnosis of atypical lipomatous tumor/well differentiated liposarcoma and dedifferentiated liposarcoma. It is also used as a screening test in high grade spindle cell or pleomorphic neoplasms. FISH is considered positive for amplification when the /CEP12 ratio is greater than 2; however, a ratio between 2 and 3 is considered a "low-level" amplification and raises the possibility of a false positive result; thus, posing a diagnostic dilemma.
View Article and Find Full Text PDF[Superficial extraskeletal osteosarcoma. Case report].
Rev Med Inst Mex Seguro Soc
March 2024
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Oncología, Anatomía Patológica. Ciudad de México, México.
Background: Osteosarcoma is the most common primary malignant bone neoplasm in young people. Presentation in non-bone tissues comprises 2 to 5% of all osteosarcomas and less than 1% of all soft tissue sarcomas. On rare occasions it presents as a superficial tumor, making it necessary to make a differential diagnosis with benign entities, such as pyogenic granuloma ossificans, and malignant neoplasms, with sarcomatoid differentiation such as carcinosarcoma and dedifferentiated melanoma.
View Article and Find Full Text PDFToripalimab in combination with chemotherapy effectively suppresses local recurrence and metastatic sarcomatoid renal cell carcinoma: A case report.
World J Clin Cases
October 2024
Department of Oncology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
Article Synopsis
- * A 77-year-old woman diagnosed with SRCC after a kidney tumor was surgically removed experienced recurrence and metastasis but responded to a combination treatment of toripalimab and pirarubicin, leading to a partial response.
- * After continuing with toripalimab alone, the patient enjoyed an almost-complete response and has remained disease-free for 15 months, suggesting that combining immune therapy with traditional chemotherapy could be effective for treating SRCC.
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).
Target Oncol
November 2024
Oncology Unit, Macerata Hospital, Macerata, Italy.
Article Synopsis
- Advances in immuno-oncology have improved treatment for renal cell carcinoma, but patients with "primary refractory" disease have poor outcomes; our study found a 19% prevalence of this group among 1,709 metastatic clear cell patients across 72 centers in 22 countries.
- The highest primary refractory rate was 27% with nivolumab/ipilimumab, while pembrolizumab/lenvatinib had the lowest at 10%; those classified as primary refractory only had a median survival of 7.6 months compared to 55.7 months for non-primary refractory patients.
- Significant predictors of survival for primary refractory patients included factors like prior nephrectomy and presence of bone/brain metastases, highlighting the complex
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!